Iovance Biotherapeutics Inc. has released a corporate presentation detailing its achievements and ongoing initiatives in the field of Tumor Infiltrating Lymphocytes $(TIL)$ therapy for cancer treatment. The company has treated over 1,000 commercial and clinical patients with its TIL products and reported more than $210 million in total product revenue. Their portfolio includes two approved products and numerous clinical trials across various cancer types, including advanced melanoma and non-small cell lung cancer. Iovance is actively involved in regulatory filings beyond the U.S. and continues to expand its treatment centers globally. The presentation highlights the company's focus on developing innovative therapies to address unmet medical needs. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。